Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by indaknownewfieon May 27, 2020 4:27pm
253 Views
Post# 31079892

Word about Beetlebung Pharma

Word about Beetlebung Pharma So they already have a patent for the glycine3 receptor but their second patent is just as exciting. That covers simplified chemical synthesis of CBD, CBDV, THC, THCV, CBG, CBN, CBC, HU-308 and any derivatives thereof. If you read through the patent application, because it was synthetic they are able to replicate very strong yields of each of these cannabinoids. 

Lets not forget that Kaly will automatically get three US patents for the use of injectable nitric oxide. Nitric oxide being tested in three major clinical trials , one 470 people, one 120 people, and a third smaller. All covid patients. Nitric oxide is already FDA approved for other indications so if these trials are succesful, it will be monetized quickly. The trials are for nitric oxide gas through inhalation but our patent is an injectable form that is superior to that and is time released evenly over 48 hrs. 
<< Previous
Bullboard Posts
Next >>